This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed Articles by SoRelle, R.

(Circulation. 2003;107:e9012.)
© 2003 American Heart Association, Inc.

Cardiovascular News

Ruth SoRelle, MPH

Circulation Newswriter

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The current issue of Circulation marks the second appearance of the journal’s new section, Mini-Review: Expert Opinions. The section is designed to provide assistance to physicians and care givers of patients with cardiovascular disease and to stimulate future research on pertinent topics. The topic featured in this week’s issue is Stem Cell Therapy and includes a review article by Bodo Strauer, MD, and Ran Kornowski, MD, a review article by Emerson Perin, MD, PhD, Yong-Jian Geng, MD, PhD, and James T. Willerson, MD, and an Editorial comment by Dean Kereiakes, MD, FACC.

CURE: Early and Late
Clopidogrel reduced the risk of ischemic vascular events as early as 24 hours after the beginning of treatment and continued for a year, according to the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) investigators, led by Salim Yusuf, MBBS, of McMaster University in Hamilton, Canada. Their report appears in this week’s issue of Circulation (Circulation. 2003;107:966–972).

In the study, 12 562 patients with acute coronary syndromes were randomized to receive either clopidogrel or placebo for 3 to 12 months. Dosage of clopidogrel began with 300 mg at the beginning and was followed by 75 mg/day for the duration of the study.

At 30 days, 5.4% of patients in the placebo group and 4.3% in the clopidogrel group had experienced either death from heart disease, heart attack, or stroke. Beyond 30 days, the rates were 6.3% in the placebo group and 5.2% in the clopidogrel group. The difference in life-threatening bleeding incidents was not statistically . . . [Full Text of this Article]